Eli Lilly and Co

FDA approved tirzepatide (Zepbound) for moderate-to-severe obstructive sleep apnea (OSA) and obesity in adults, based on SURMOUNT-OSA trials showing improvements in apnea-hypopnea index and weight loss. Tirzepatide was 5 times more effective than placebo in reducing breathing disruptions, leading to fewer disruptions per hour and higher rates of OSA remission or mild symptoms.

FDA approves Zepbound for treating obstructive sleep apnea in moderately or severely obese individuals, to be used with a reduced-calorie diet and physical activity. Zepbound showed significant improvements in reducing breathing disruptions and aiding weight loss, with nearly half of clinical trial patients no longer experiencing OSA symptoms.

Annabelle Black and Nathan Parker, high school seniors from Dearborn County, received the 2025 Lilly Endowment Community Scholarship, covering full tuition, fees, and books for four years. The scholarship aims to enhance educational attainment in Indiana and support community foundations. The Dearborn Community Foundation administers the program, selecting finalists through a rigorous process involving essays, interviews, and presentations.

Novo Nordisk's next-gen obesity drug, CagriSema, showed lower-than-expected weight loss in late-stage trials, causing a $100 billion market value drop. The phase III trial results were closely watched as a successor to blockbuster Wegovy.

The US FDA approved tirzepatide (Zepbound) on December 20, 2024, for adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity. Tirzepatide significantly improves OSA and aids in long-term weight loss, with nearly half of clinical trial patients seeing symptom improvements. This marks the second indication for tirzepatide, following its approval for obesity in November 2023. The approval was supported by the SURMOUNT-OSA phase 3 clinical trial, showing tirzepatide's efficacy in reducing apnea-hypopnea index (AHI) and promoting substantial weight loss.

FDA approved Zepbound as the first prescription medicine for sleep apnea, marking a significant win for Eli Lilly. Zepbound, already approved for weight loss, can now be prescribed for adults with moderate-to-severe obstructive sleep apnea and obesity, improving sleep quality and reducing weight.

The FDA approved Eli Lilly's Zepbound for moderate to severe obstructive sleep apnea in adults with obesity, marking the first drug for the condition. Zepbound, containing tirzepatide, aids in reducing food cravings and stomach emptying, with trials showing it resolved the disorder in up to 52% of patients. Lilly's shares rose 1.14% post-approval.

Novo Nordisk's experimental diabetes and weight-loss drug CagriSema fell short of expectations, achieving 22.7% weight loss vs. projected 25%. The stock dropped over 20%.

Inter-American Court of Human Rights ruled El Salvador violated a woman's rights in a 2013 abortion case. GSK's cancer drug combination met major goals in trials. Novo Nordisk faced investor discontent over its obesity drug trial. Vertex made a cystic fibrosis breakthrough, and Eli Lilly received FDA approval for a sleep apnea weight-loss drug.

FDA clears Eli Lilly's Zepbound for treating obesity and moderate-to-severe obstructive sleep apnea, marking its first approval beyond weight loss.